If in-depth in vivo/vitro studies can be conducted on this basis to clarify the mechanism of these regulators (TRMT6, TRMT61A, TRMT10C, and YTHDF1), they will provide promising targeted intervention strategies for HCC therapy. This evidence concerns the gene YTHDF1 and hepatocellular carcinoma.